Capecitabine, Oxaliplatin and Radiotherapy: A Phase IB Neoadjuvant Study for Esophageal Cancer with Gene Expression Analysis

REFERENCES

• Fischel J. L., Etienne M. C., Formento P., et al. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998; 4: 2529–2535
   PubMed Web of Science ®Google Scholar
• Oxaliplatin (Eloxatin) for advanced colon cancer. Med Lett Drugs Ther 2003; 45: 7–8
   PubMed Web of Science ®Google Scholar
• Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–2351
   PubMed Web of Science ®Google Scholar
• Van C. E., Verslype C., Demedts I. The treatment of advanced colorectal cancer: where are we now and where do we go?. Best Pract Res Clin Gastroenterol 2002; 16: 319–330
   PubMed Web of Science ®Google Scholar
• Khushalani N. I., Leichman C. G., Proulx G., et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002; 20: 2844–2850
   PubMed Web of Science ®Google Scholar
• Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006; 107: 221–231
   PubMed Web of Science ®Google Scholar
• Cassidy J. Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Clin Colorectal Cancer 2005; 5(Suppl 1)S47–S50
   PubMedGoogle Scholar
• Navarro R. P., Morrow T., Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag. Care Interface 2002; 15: 55–62
   PubMedGoogle Scholar
• Cassidy J., Tabernero J., Twelves C., et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–2091
   PubMed Web of Science ®Google Scholar
• Scheithauer W., Kornek G. V., Raderer M., et al. Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol 2003; 21: 1307–1312
   PubMed Web of Science ®Google Scholar
• Varma R., Hector S., Greco W. R., et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother. Pharmacol. 2006
   PubMed Web of Science ®Google Scholar
• Hector S., Porter C. W., Kramer D. L., et al. Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Ther 2004; 3: 813–822
   PubMed Web of Science ®Google Scholar
• Toi M., Atiqur R. M., Bando H., et al. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6: 158–166
   PubMed Web of Science ®Google Scholar
• Hector S., Clark K., Murphy M., et al. The platinum drugs cisplatin and oxaliplatin induce carboxylesterase 2 gene expression in A2780 ovarian carcinoma cells. Proc. AACR 2003; 44: 368
   Google Scholar
• Judson I. R., Beale P. J., Trigo J. M., et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest N Drugs 1999; 17: 49–56
   PubMed Web of Science ®Google Scholar
• Mandard A. M., Dalibard F., Mandard J. C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–2686
   Google Scholar
• Therasse P., Arbuck S. G., Eisenhauer E. A., et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92: 205–216
   PubMed Web of Science ®Google Scholar
• Johnson M. R., Wang K., Smith J. B., et al. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278: 175–184
   PubMed Web of Science ®Google Scholar
• Mandard A. M., Dalibard F., Mandard J. C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–2686
   Google Scholar
• Chang F., Deere H., Mahadeva U., et al. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol 2008; 129: 252–262
   PubMed Web of Science ®Google Scholar
• Levi F., Metzger G., Massari C., et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet 2000; 38: 1–21
   PubMed Web of Science ®Google Scholar
• Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006; 107: 221–231
   PubMed Web of Science ®Google Scholar
• Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36–46
   PubMed Web of Science ®Google Scholar
• Kelsen D. P. Multimodality therapy of local regional esophageal cancer. Semin Oncol 2005; 32: S6–10
   PubMed Web of Science ®Google Scholar
• Cunningham D., Maroun J., Vanhoefer U., et al. Optimizing the use of irinotecan in colorectal cancer. Oncologist 2001; 6(Suppl 4)17–23
   PubMedGoogle Scholar
• Ajani J. A., Faust J., Yao J., et al. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncol (Williston Park) 2003; 17: 20–22
   PubMedGoogle Scholar
• Pasini F., de M. G., Pedrazzani C., et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005; 16: 1133–1139
   PubMed Web of Science ®Google Scholar
• Rigas J. R., Dragnev K. H., Bubis J. A. Docetaxel in the treatment of esophageal cancer. Semin. Oncol. 2005; 32: S39–S51
   PubMed Web of Science ®Google Scholar
• Berger A. C., Farma J., Scott W. J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330–4337
   PubMed Web of Science ®Google Scholar
• Hammoud Z. T., Kesler K. A., Ferguson M. K., et al. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus 2006; 19: 69–72
   PubMed Web of Science ®Google Scholar
• Joshi M. B., Shirota Y., Danenberg K. D., et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005; 11: 2215–2221
   PubMed Web of Science ®Google Scholar
• Luthra R., Luthra M. G., Izzo J., et al. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin. Oncol 2006; 33(Suppl 11)2–5
   PubMedGoogle Scholar
• Yamamoto M., Tsujinaka T., Shiozaki H., et al. Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy. Oncol. 1999; 56: 332–337
   Google Scholar
• Wu M. Y., Zhuang C. X., Yang H. X., et al. Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. World J Gastroenterol 2004; 10: 476–480
   PubMed Web of Science ®Google Scholar
• Nakamura T., Hayashi K., Ota M., et al. Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis. Esophagus 2004; 17: 315–321
   PubMed Web of Science ®Google Scholar
• Warnecke-Eberz U., Hokita S., Xi H., et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005; 13: 1241–1246
   PubMed Web of Science ®Google Scholar
• Kajiyama Y., Hattori K., Tomita N., et al. Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivariate analysis of predictive factors and p53 overexpression. Dis. Esophagus 2002; 15: 61–66
   PubMed Web of Science ®Google Scholar
• Luthra R., Wu T. T., Luthra M. G., et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006; 24: 259–267
   PubMed Web of Science ®Google Scholar
• Leichman L., Lawrence D., Leichman C. G., et al. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother 2006; 18: 514–524
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J., Lenz H. J. Implications of genetic testing in the management of colorectal cancer. Am J Pharmacogenomics 2003; 3: 73–88
   PubMedGoogle Scholar
• Xi H., Baldus S. E., Warnecke-Eberz U., et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005; 11: 8341–8347
   PubMed Web of Science ®Google Scholar
• Schneider S., Uchida K., Brabender J., et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005; 200: 336–344
   PubMed Web of Science ®Google Scholar